Ensysce Biosciences (ENSC) Non-Current Debt (2019 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Non-Current Debt of $306708.0 for Q4 2025, up 1.67% year-over-year from $301660.0 in Q4 2024, and down 20.89% quarter-over-quarter from $387702.0 in Q3 2025.
Ensysce Biosciences (ENSC) Non-Current Debt (2019 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Non-Current Debt for 7 consecutive years, with $306708.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Debt rose 1.67% year-over-year to $306708.0; the TTM figure through Dec 2025 stood at $306708.0 (up 1.67% YoY), while the FY2025 annual figure was $306708.0, up 1.67% from the prior year.
- Non-Current Debt declined to $306708.0 in Q4 2025 per ENSC's latest filing, from $387702.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $8.9 million in Q3 2022 and bottomed at $140148.0 in Q4 2022.
- Historically, Non-Current Debt has averaged $1.4 million across 5 years, with a median of $435129.5 in 2023.
- On a YoY basis, Non-Current Debt climbed as much as 834.05% in 2022 and fell as far as 96.84% in 2022.
- Ensysce Biosciences' Non-Current Debt stood at $4.4 million in 2021, then plunged by 96.84% to $140148.0 in 2022, then jumped by 509.85% to $854697.0 in 2023, then plunged by 64.71% to $301660.0 in 2024, then climbed by 1.67% to $306708.0 in 2025.
- Business Quant data shows ENSC's Non-Current Debt at $306708.0 in Q4 2025, $387702.0 in Q3 2025, and $424521.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | Ensysce Biosciences | 960,039.34 | -3.35 Mn | - | 306,708.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 306,708.00 |
| Sep 30, 2025 | 387,702.00 |
| Jun 30, 2025 | 424,521.00 |
| Mar 31, 2025 | 257,383.00 |
| Dec 31, 2024 | 301,660.00 |
| Sep 30, 2024 | 387,176.00 |
| Jun 30, 2024 | 454,463.00 |
| Mar 31, 2024 | 245,973.00 |
| Dec 31, 2023 | 854,697.00 |
| Sep 30, 2023 | 350,932.00 |
| Jun 30, 2023 | 445,738.00 |
| Dec 31, 2022 | 140,148.00 |
| Sep 30, 2022 | 8.94 Mn |
| Jun 30, 2022 | 4.24 Mn |
| Mar 31, 2022 | 871,409.00 |
| Dec 31, 2021 | 4.44 Mn |
| Sep 30, 2021 | 957,099.00 |
| Jun 30, 2021 | 466,055.00 |
| Dec 31, 2020 | 4.25 Mn |
| Sep 30, 2020 | 566,268.00 |